### **Session Four**

Panel
What Do the Data Tell Us? What
Can We Learn From the Latest
Colorectal Cancer Screening
Rate Trends Over Time?





2:20 PM to 3:25 PM

### **Panel**

## What Do the Data Tell Us? What Can We Learn From the Latest Colorectal Cancer Screening Rate Trends Over Time?













# What Do the Data Tell Us About CRC Screening? The National Health Interview Survey

Priti Bandi, PhD
Scientific Director, Risk Factors & Screening Research
American Cancer Society

What Do the Data Tell Us About CRC Screening? The National Health Interview Survey.



Priti Bandi November 2023



# NHIS

### National Health Interview Survey

- In person, nationally representative, household survey among noninstitutionalized adults
- Self-reported CRC screening data
  - Colonoscopy
  - Sigmoidoscopy
  - FIT/gFOBT (hereafter FIT)
  - CT Colonography (added in 2010)
  - sDNA/Cologuard (added in 2018)
- 2019: Change in survey design, CRC screening questions, and rotation
- 2021: CRC screening data are collected, mix of in-person/telephone





National Health Interview Survey

#### American Cancer Society

# Cancer Prevention & Early Detection Facts & Figures

National and state-level screening data


- ACS Bi-annual surveillance publication
- 2023-2024 latest
- Tables and Figures updated every year
- Historical back to 2006

American Cancer Society. *Cancer Prevention & Early Detection Facts & Figures, 2023-2024*.

https://www.cancer.org/research/cancer-factsstatistics/cancer-prevention-early-detection.html



# Trends in Breast\*, Cervical<sup>†</sup>, and Colorectal<sup>‡</sup> Cancer Screening (%), US, 2000-2021





Source: National Health Interview Survey, 2000-2021









American Cancer Society



BRFSS BARRISS Street Surveillance System

Original Investigation | Diversity, Equity, and Inclusion

#### Changes in Cancer Screening in the US During the COVID-19 Pandemic

Stacey A. Fedewa, PhD; Jessica Star, MA, MPH; Priti Bandi, PhD; Adair Minihan, MPH; Xuesong Han, PhD; K. Robin Yabroff, MBA, PhD; Ahmedin Jemal, DVM, PhD



# Cancer Screening in the United States During the Second Year of the COVID-19 Pandemic

Journal of Clinical Oncology



Jessica Star, MA, MPH<sup>1</sup>; Priti Bandi, PhD<sup>1</sup>; Rebecca L. Siegel, MPH<sup>1</sup>; Xuesong Han, PhD<sup>1</sup>; Adair Minihar Robert A. Smith, PhD<sup>2</sup>; and Ahmedin Jemal, DVM, PhD<sup>1</sup>

CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION | REVIEW

Updated Review of Major Cancer Risk Factors and Screening Test use in the United States, with a Focus on Changes During the COVID-19 Pandemic

Jessica Star<sup>1</sup>, Priti Bandi<sup>1</sup>, Nigar Nargis<sup>1</sup>, Farhad Islami<sup>1</sup>, K. Robin Yabroff<sup>1</sup>, Adair K. Minihan<sup>1</sup>, Robert A. Smith<sup>2</sup>, and Ahmedin Jemal<sup>1</sup>

Cancer Epidemiology, Biomarkers & Prevention





## Cancer Screening in the United States During the Second Year of the COVID-19 Pandemic

**Journal** of Clinical Oncology®

Jessica Star, MA, MPH<sup>1</sup>; Priti Bandi, PhD<sup>1</sup>; Rebecca L. Siegel, MPH<sup>1</sup>; Xuesong Han, PhD<sup>1</sup>; Adair Minihan, MPH<sup>1</sup> Robert A. Smith, PhD<sup>2</sup>; and Ahmedin Jemal, DVM, PhD<sup>1</sup> CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION | REVIEW


Updated Review of Major Cancer Risk Factors and Screening Test use in the United States, with a Focus on Changes During the COVID-19 Pandemic

Epidemiology, Biomarkers & Prevention


Cancer

Jessica Star<sup>1</sup>, Priti Bandi<sup>1</sup>, Nigar Nargis<sup>1</sup>, Farhad Islami<sup>1</sup>, K. Robin Yabroff<sup>1</sup>, Adair K. Minihan<sup>1</sup>, Robert A. Smith<sup>2</sup>, and Ahmedin Jemal<sup>1</sup>

### Past Year Colorectal Cancer Screening



### **Up to Date Colorectal Cancer Screening**




Large increase in stool-based testing offset a decline in past-year colonoscopy; and contributed to small increase in UTD screening

#### **Cancer Screening in the United States During the Second Year of the** COVID-19 Pandemic

Journal of Clinical Oncology®


Jessica Star, MA, MPH1; Priti Bandi, PhD1; Rebecca L. Siegel, MPH1; Xuesong Han, PhD1; Adair Minihan, MPH1 Robert A. Smith, PhD2: and Ahmedin Jemal, DVM, PhD1




CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION | REVIEW

Jessica Star<sup>1</sup>, Priti Bandi<sup>1</sup>, Nigar Nargis<sup>1</sup>, Farhad Islami<sup>1</sup>, K. Robin Yabroff<sup>1</sup>, Adair K. Minihan<sup>1</sup>, Robert A. Smith<sup>2</sup>, and Ahmedin Jemal<sup>1</sup>

Cancer Epidemiology, Biomarkers & Prevention






### Past-year and UTD prevalence increased in Hispanic people driven by stool testing increase



# 2021 prevalence

### Age differences: CRC Screening Prevalence, Ages ≥45 years, 2021






\*Fecal occult blood test (FOBT) OR fecal immunochemical test (FIT) within the past 1 year OR s DNA test within the past 3 years. †Within the past 10 years. ‡FOBT/FIT, sigmoidoscopy, colonoscopy, computed tomography (CT) colonography, OR sDNA test in the past 1, 5, 10, 5 and 3 years, respectively.

Source: National Health Interview Survey, 2000-2021



### Race/ethnicity: CRC Screening Prevalence, Ages ≥45 years, 2021






\*Fecal occult blood test (FOBT) OR fecal immunochemicaltest (FIT) within the past 1 year OR s DNA test within the past 3 years. †Within the past 10 years. ‡FOBT/FIT, sigmoidoscopy, colonoscopy, computed tomography (CT) colonography, OR sDNA test in the past 1, 5, 10, 5 and 3 years, respectively.

Source: National Health Interview Survey, 2000-2021

### Insurance: CRC screening prevalence, Ages 45+ years, 2021





\*Fecal occult blood test (FOBT) OR fecal immunochemical test (FIT) within the past 1 year OR s DNA test within the past 3 years. †Within the past 10 years. ‡FOBT/FIT, sigmoidoscopy, colonoscopy, computed tomography (CT) colonography, OR sDNA test in the past 1, 5, 10, 5 and 3 years, respectively.

Source: National Health Interview Survey, 2000-2021

### Summary

- COVID-19 pandemic: Large increase in stool-based testing
  - Maintained up-to-date CRC screening
  - Mitigate sociodemographic disparities
- Race/ethnic and Insurance disparities in CRC screening persist: social and structural barriers need to be addressed alongside patient and healthcare factors
- Newly-eligible adults 45-49 years: concerted efforts needed to increase low prevalence





# Thanks.

©2023, American Cancer Society, Inc.





### Thank You

nccrt.org @NCCRTnews #80inEveryCommunity





### 2022 UDS Update Colorectal Cancer Screening

#### Neeraj Deshpande MBBS, MPH, MHA

Public Health Analyst, Quality Recognition and Health Promotion Team Bureau of Primary Health Care/Office of Quality Improvement DHHS/Health Resources and Services Administration (virtual)





### Thank You

nccrt.org @NCCRTnews #80inEveryCommunity





# What Do the Data Tell Us? What Can We Learn from the Latest Colorectal Cancer Screening Rate Trends Over Time?

Peter Liang, MD, MPH
Assistant Professor, Department of Medicine and Department of Population Health
NYU Langone Health
ACS NCCRT Steering Committee



NCCRT Annual Meeting

Nov 15, 2023

# What Do the Data Tell Us? What Can We Learn from the Latest Colorectal Cancer Screening Rate Trends over Time?

Peter S. Liang, MD MPH
Departments of Medicine and Population Health, NYU Langone Health
VA New York Harbor Health Care System
NYC Health + Hospitals Bellevue

### **Disclosures**

Research support: Epigenomics, Freenome

Advisory board: Guardant Health


### **HEDIS Measures**

### HEDIS Screening Rates Medicare and Commercial, ages 50-75 (45-75 in 2022)

\*Screening rate data for Medicare plans is not available for 2019 because CMS suspended Medicare quality reporting requirements in response to COVID-19.

\*Trending caution: added required exclusion to the Medicare product line for members 65 years of age and older living long-term in institutional settings.

\*Trending caution: there is a break in trending for the Commercial and Medicare product lines for the total rate due to the expansion of the age criteria from 50–75 to 45–75 years.




# Racial and ethnic disparities: if you can't measure it, you can't address it


Office and Management and Budget (OMB) Racial and Ethnic Categories and Alternative Disaggregated Categories

ОМВ	HHS	New York State
American		
Indian or		
Alaska Native		
Asian	7 subgroups: Asian	20 subgroups: 7 HHS subgroups, Laotian,
	Indian, Chinese,	Cambodian, Bangladeshi, Hmong,
	Filipino, Japanese,	Indonesian, Malaysian, Pakistani, Sri Lankan,
	Korean, Vietnamese,	Taiwanese, Nepalese, Burmese, Tibetan,
	Other Asian	Thai
Black or African		
American		
Hispanic or	4 subgroups:	
Latino	Mexican/Mexican	
	American/Chicano/a,	
	Puerto Rican, Cuban,	
	Another	
	Hispanic/Latino/Spanish	
	origin	
Native	4 subgroups: Native	6 subgroups: 4 HHS subgroups, Fijian,
Hawaiian or	Hawaiian, Guamanian	Tongan
Other Pacific	or Chamorro, Samoan,	
Islander	Other Pacific Islander	
White		

# When data for different racial and ethnic groups was collected



# Proposed detailed & minimum categories for combined race and ethnicity data collection



What is your race or ethnicity?  Select all that apply.			
☐ White			
☐ Hispanic or Latino			
☐ Black or African American			
☐ Asian			
☐ American Indian or Alaska Native			
☐ Middle Eastern or North African			
☐ Native Hawaiian or Pacific Islander			

### Major proposed changes

- 1) Race and ethnicity collected using a combined question
- 2) New minimum category: Middle Easter or North African (MENA)
- 3) Requires collection of detailed categories by default

### Benefits of proposed changes

What is your race or eth	-00000 Feb	
Select all that apply AND Note, you may report mo		tails in the spaces below.
□ WHITE - Provide deta		
		T contint
☐ German	☐ Irish	☐ English
☐ Italian	☐ Polish	☐ French
Enter, for example, So	ottish, Norwegian, L	outen, etc.
☐ HISPANIC OR LATING	– Provide details be	elow.
Mexican or Mexican American		☐ Cuban
☐ Salvadoran	☐ Dominican	☐ Colombian
Enter, for example, G	uatemalan, Spaniaro	d, Ecuadorian, etc.
		1 .
☐ BLACK OR AFRICAN A	MERICAN - Provide	details below.
☐ African American	☐ Jamaican 🌰	☐ Haitian
☐ Nigerian	☐ Ethiopian	☐ Somali
Enter, for example, G	hanaian, South Afric	an, Barbadian, etc.
☐ ASIAN - Provide detail	ils below.	7
☐ Chinese	☐ Filipino	☐ Asian Indian
☐ Vietnamese	☐ Korean	☐ Japanese
Enter, for example, Po	akist <mark>ani, Cambod</mark> ian	, Hmong, etc.
□ AMERICAN INDIAN O Navajo Nation, Blackf Barrow Inupiat Tribal	eet Tribe, Mayan, A	ztec, Native Village of
	<del># 11                                  </del>	
☐ MIDDLE EASTERN OR	NORTH AFRICAN -	Provide details below.
□ Lebanese	☐ Iranian	☐ Egyptian
☐ Syrian	☐ Moroccan	☐ Israeli
Enter, for example, Al	lgerian, Iraqi, Kurdisi	h, etc.
☐ NATIVE HAWAIIAN O	R PACIFIC ISLANDER	R – Provide details below.
☐ Native Hawaiian	☐ Samoan	☐ Chamorro
☐ Tongan	☐ Fijian alauan, Tahitian, Chi	☐ Marshallese

### **Proposed changes**

- 1) Race and ethnicity collected using a combined question
- 2) New minimum category: Middle Easter or North African (MENA)
- 3) Requires collection of detailed categories by default

### **Potential benefits**

- 1) Reduces number of ppl who select "Some Other Race"
- 2) Reflects increasing demographic diversity and how ppl self-identify
- 3) Captures disparities in more granular way





### Thank You

nccrt.org @NCCRTnews #80inEveryCommunity







Colorectal Cancer Screening 45-49yo BRFSS 2022



# BRFSS Population 45-49yo, Colorectal Cancer Screening, 2022

- 25,873 men and women 45-49yo in BRFSS sample
- Weighted population estimate
  - ~16 million men and women 45-49yo in the US
- Colorectal Cancer Screening
  - 31% Up-to-date with CRC screening
  - 4.2% Screened but not up-to-date
  - 64.7% Never screened

